Saniona’s focus is on the discovery and development of proprietary product candidates for the treatment of epilepsy and other CNS diseases with high unmet medical need.
INVESTMENT RATIONALE
1. Proprietary ion-channel drug discovery engine driving pipeline
SAN711: For rare neuropathic disorders, in Phase 1
SAN903: For rare inflammatory/fibrotic disorders (e.g. IPF), in preclinical
Library: 20,000 proprietary ion channel modifiers
2. Validation from multiple strategic partnerships
 |  |  |
| Medix: Tesofensine for obesity | Novartis: CAD-1883 for movement disorders | Boehringer Ingelheim: Novel target for schizophrenia |
Why epilepsy?
Epilepsy is one of the most common and disabling chronic neurological disorders and currently affects more than 50 million people worldwide. There is a significant medical need as approximately 30 percent of patients are insensitive to treatment by conventional epilepsy medicines.
The aetiology of epilepsy includes a variety of causes including genetic mutations, autoimmune diseases as well as acquired cases such as stroke, traumatic brain injury, and infectious diseases of the brain.
Ion channels, the core competence of Saniona, are deeply involved in controlling aberrant electrical activity in the brain and the generation of epilepsy, and are attractive targets for the development of innovative, effective, and well tolerated new epilepsy medicines.